Mankind Pharma Introduces Dydroboon 30mg Sustained Release Tablets for Treatment of Endometriosis

Opening doors to convenience for patients suffering from endometriosis, Mankind Pharma, a leading Indian pharmaceutical company, has announced the launch of Dydroboon 30mg Sustained Release tablets in India.

Dydroboon 30mg is approved by DCGI for the treatment of endometriosis. It contains Dydrogesterone 30 mg in the sustained-release tablet dosage form.

Women suffering from endometriosis have to consume 2-3 pills of Dydrogesterone daily, increasing their pill burden. Dydroboon 30mg sustained release tablets ensure drug release for a longer time, mitigating this practical burden of treatment inconvenience. It increases the chances of treatment adherence and helps the patient with the convenience of once daily dose of the drug.

Dydrogesterone is a synthetic progestogen that works similarly to progesterone. It addresses menstrual disorders arising from hormonal imbalances in women. Dydroboon Tablet effectively treats various conditions caused by progesterone deficiencies, such as female infertility, pain during menstruation, premenstrual syndrome (PMS), endometriosis, abnormal uterine bleeding, and miscarriage.

Commenting on the launch Mr. Rajeev Juneja, Vice-Chairman & Managing Director, Mankind pharma said “Our commitment to patient well-being drives our innovations. The launch of Dydroboon 30mg Sustained Release Tablets reinforces our mission to enhance the lives of millions of women battling endometriosis. As the 1st Indian company and 2nd in the world to launch Dydrogesterone for Indian patients, we continuously focus on providing women with treatment solutions that not only provide clinical efficacy but also offer convenience, freeing patients from the daily challenge of managing multiple pills.”

Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by Mankind Pharma.